Anti-Cancer Agents in Medicinal Chemistry-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2024-07-25 ms7000000138744330 来自江苏省

偏重的研究方向：肿瘤
经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？

90 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2024-05-23 ms2000001598305158 来自云南省

投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？

142 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2022-02-23 ms1000000685506334

40天了，还在初始检查，不知道啥时候能送外省，真的好慢

140 6 举报

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2023-09-26 120f1421m20暂无昵称来自浙江省

请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失

134 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2022-12-05 ms7000001568236747 来自天津

请问图片处理费是必须要交的吗

147 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2023-01-24 ms4000001619666953 来自重庆

大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑

140 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2021-12-28 Gym璨烨

如何判断两种药物之间是协同作用还是相加作用？

163 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2023-02-03 ms4000001610031172 来自山东省

审稿速度:24.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤药物
经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！

133 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2022-12-02 ms4000001619666953 来自重庆

都大半个月了还在初始检查是正常的吗，真的好焦急

146 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216860, encodeId=2ea622168600d, content=偏重的研究方向：肿瘤 经验分享：初步审查后，有要求提交所有作者简历的嘛？还有动物实验那个表格怎么填啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Thu Jul 25 20:18:29 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2206137, encodeId=10a1220613ea7, content=投稿后收到的确认投稿邮件里有这样一句话“Please note that your article will not be processed till you have completed and returned the attached fee form by replying to this e-mail.”但是选的是OA也没有走快速通道，是否需要联系咨询缴费事宜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c556144951, createdName=ms2000001598305158, createdTime=Thu May 23 09:35:50 CST 2024, time=2024-05-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1196311, encodeId=340f11963111e, content=40天了，还在初始检查，不知道啥时候能送外省，真的好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e00b5497145, createdName=ms1000000685506334, createdTime=Wed Feb 23 08:57:42 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159839, encodeId=24a42159839e7, content=请问下发表过该期刊的老师们，我的文章在网页里显示是ready to publish，在pubmed上也可以搜索到，但是期刊没有卷期，发邮件去问，对方让我付版面费才能看到全文，我不是很明白是什么意思，该杂志不是非OA吗？且也没有任何让我付费的邮件和付费的端口。如果我不想得到我的全文，是不是不付费也可以的？文章应该是确定发表了吧？患得患失, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5512218233, createdName=120f1421m20暂无昵称, createdTime=Tue Sep 26 16:50:06 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104473, encodeId=279221044e3e9, content=请问图片处理费是必须要交的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aafe5596436, createdName=ms7000001568236747, createdTime=Mon Dec 05 20:12:35 CST 2022, time=2022-12-05, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2111278, encodeId=be6521112e897, content=大家一审大概多久啊，被拒的概率大吗，已经送外审快两个月了，等得好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Tue Jan 24 06:40:19 CST 2023, time=2023-01-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1100972, encodeId=756211009e2fd, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112858, encodeId=d99c21128586f, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿半男，最终等来的是没有找到审稿人给拒稿，真的是无语杂志，不建议投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Fri Feb 03 10:47:03 CST 2023, time=2023-02-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104021, encodeId=86162104021b4, content=都大半个月了还在初始检查是正常的吗，真的好焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1218312306, createdName=ms4000001619666953, createdTime=Fri Dec 02 22:43:47 CST 2022, time=2022-12-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2094883, encodeId=8748209488377, content=投稿命中率:50.0 偏重的研究方向：肿瘤药物 经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e935571138, createdName=ms4000001610031172, createdTime=Thu Oct 20 08:48:08 CST 2022, time=2022-10-20, status=1, ipAttribution=)]

2022-10-20 ms4000001610031172

投稿命中率:50.0
偏重的研究方向：肿瘤药物
经验分享：投稿一个半月了，还没有消息，图片预处理费用也交了，怎么这么慢吗？有了解的吗？

0 2 举报

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务